JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• TMS for Post Stroke Depression

  NCT04093843

  Condition:   Post-stroke Depression
  Intervention:   Device: TMS
  Sponsor:   Amelia Adcock
  Recruiting
• Two Year Study With Robotic-Arm Assisted Hip Surgery.

  NCT03891199

  Conditions:   Surgery;   Hip Osteoarthritis
  Intervention:   Procedure: Robotic-Arm Assisted THA
  Sponsors:   West Virginia University;   Stryker Nordic;   West Penn Allegheny Health System
  Recruiting
• Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells

  NCT03861598

  Conditions:   Glioblastoma Multiforme;   Glioblastoma
  Intervention:   Drug: Carvedilol
  Sponsors:   West Virginia University;   West Virginia Clinical and Translational Science Institute
  Recruiting
• Use of Tele-Exercise for Translating an Evidence-Based Fall-Prevention Program for Older Adults in West Virginia

  NCT03714100

  Condition:   Accidental Falls
  Intervention:   Behavioral: Tai Ji Quan: Moving for Better Balance
  Sponsor:   West Virginia University
  Recruiting
• A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

  NCT03602911

  Condition:   Head and Neck Squamous Cell Carcinoma
  Intervention:   Drug: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
  Sponsor:   West Virginia University
  Recruiting
• Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

  NCT03111121

  Conditions:   Microlaryngoscopy;   Rigid Bronchoscopy
  Interventions:   Drug: Sugammadex;   Drug: neostigmine;   Drug: glycopyrrolate
  Sponsor:   West Virginia University
  Recruiting
• Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

  NCT04024800

  Condition:   Triple-negative Breast Cancer
  Interventions:   Biological: AE37 Peptide vaccine;   Biological: Pembrolizumab
  Sponsors:   Antigen Express, Inc;   Merck Sharp & Dohme Corp.;   NSABP Foundation Inc
  Recruiting
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

  NCT03662204

  Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma

  NCT02972840

  Condition:   Lymphoma, Mantle Cell
  Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
  Sponsor:   Acerta Pharma BV
  Recruiting
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693

  Condition:   Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
  Interventions:   Drug: FDC macitentan/tadalafil;   Drug: Macitentan 10 mg;   Drug: Tadalafil 40 mg;   Drug: Placebo FDC;   Drug: Placebo macitentan;   Drug: Placebo tadalafil
  Sponsors:   Actelion;   Covance;   Almac Clinical Technologies;   WorldCare Clinical;   Frontier Science Foundation
  Recruiting
• Longitudinal Performance of Epi proColon

  NCT03218423

  Conditions:   Colorectal Cancer;   Colorectal Neoplasms
  Intervention:   Device: Epi proColon
  Sponsor:   Epigenomics, Inc
  Recruiting
• Clinical Trial of BP1001(Liposomal Grb2 Antisense Oligonucleotide) in Combination With Decitabine in AML / High Risk MDS

  NCT02781883

  Conditions:   Acute Myeloid Leukemia (AML);   High-risk Myelodysplastic Syndrome
  Intervention:   Drug: BP1001 in combination with decitabine
  Sponsor:   Bio-Path Holdings, Inc.
  Recruiting
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635

  Condition:   Smoldering Plasma Cell Myeloma
  Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

  NCT03930732

  Condition:   Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Dupilumab SAR231893;   Drug: Inhaled Corticosteroid;   Drug: Inhaled Long-Acting Beta Agonist;   Drug: Inhaled Long-Acting Muscarinic Antagonist;   Drug: Placebo
  Sponsors:   Sanofi;   Regeneron Pharmaceuticals
  Recruiting
• OTO-313 in Subjects With Subjective Tinnitus

  NCT03918109

  Condition:   Tinnitus, Subjective
  Interventions:   Drug: OTO-313;   Drug: Placebo
  Sponsor:   Otonomy, Inc.
  Recruiting
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612

  Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Endometrial Clear Cell Adenocarcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Mixed Cell Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Endometrial Undifferentiated Carcinoma;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

  NCT03891446

  Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
  Intervention:   Drug: Bimatoprost SR
  Sponsor:   Allergan
  Recruiting
• Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

  NCT03853694

  Conditions:   Elective Cesarean Section;   Pain Management
  Interventions:   Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen;   Drug: 150 mcg Duramorph + multi-modal pain regimen;   Drug: Exparel TAP + multi-modal pain regimen
  Sponsor:   Pacira Pharmaceuticals, Inc
  Recruiting
• Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

  NCT03833154

  Condition:   Carcinoma, Non-Small-Cell Lung
  Interventions:   Drug: Durvalumab;   Other: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

  NCT03822351

  Conditions:   Stage III Non-small Cell Lung Cancer;   Unresectable
  Interventions:   Drug: Durvalumab + Oleclumab;   Drug: Durvalumab;   Drug: Durvalumab + Monalizumab
  Sponsor:   MedImmune LLC
  Recruiting
• A Disease Registry of Patients With Mantle Cell Lymphoma

  NCT03816683

  Condition:   Mantle Cell Lymphoma
  Intervention:  
  Sponsor:   AstraZeneca
  Recruiting
• Sleep for Stroke Management and Recovery Trial

  NCT03812653

  Conditions:   Ischemic Stroke;   Sleep Apnea;   Sleep Apnea, Obstructive;   TIA;   Stroke;   CPAP;   Telemedicine;   Home Sleep Apnea Test;   Randomized Clinical Trial;   Multicenter Trial
  Intervention:   Device: CPAP
  Sponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   FusionHealth LLC;   Medical University of South Carolina;   University of Cincinnati
  Recruiting
• Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer

  NCT03801902

  Conditions:   Lung Non-Small Cell Carcinoma;   PD-L1 Overexpression;   Recurrent Lung Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
  Interventions:   Biological: Durvalumab;   Radiation: Fractionated Stereotactic Radiation Therapy;   Radiation: Hypofractionated Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Durvalumab;   Other: Placebo;   Drug: Carboplatin/Paclitaxel;   Drug: Cisplatin/Gemcitabine;   Drug: Pemetrexed/Cisplatin;   Drug: Pemetrexed/Carboplatin
  Sponsor:   AstraZeneca
  Recruiting
• Diabetic Gastroparesis Study 05

  NCT03786380

  Condition:   Gastroparesis
  Intervention:   Drug: Relamorelin 10 μg
  Sponsor:   Allergan
  Recruiting
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

  NCT03777436

  Condition:   Psoriasis
  Interventions:   Drug: Apremilast;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

  NCT03737851

  Condition:   Multiple Sclerosis (MS)
  Interventions:   Drug: elezanumab;   Drug: placebo
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

  NCT03737812

  Condition:   Multiple Sclerosis (MS)
  Interventions:   Drug: elezanumab;   Drug: placebo
  Sponsor:   AbbVie
  Recruiting
• AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

  NCT03732794

  Conditions:   Atrial Fibrillation;   Persistent Atrial Fibrillation;   Longstanding Persistent Atrial Fibrillation
  Intervention:   Device: AtriCure CryoICE & AtriClip LAA Exclusion
  Sponsor:   AtriCure, Inc.
  Recruiting
• Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

  NCT03727100

  Condition:   Lumbosacral Radiculopathy
  Interventions:   Combination Product: Clonidine Micropellets;   Other: Sham
  Sponsors:   Sollis Therapeutics, Inc.;   Lotus Clinical Research, LLC
  Recruiting
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

  NCT03721172

  Condition:   Psoriasis
  Interventions:   Drug: Apremilast;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

  NCT03720470

  Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Dupilumab;   Drug: Oral Placebo;   Drug: Injectable Placebo
  Sponsor:   Pfizer
  Recruiting
• Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

  NCT03719300

  Condition:   Non-muscle Invasive Bladder Cancer (NMIBC)
  Intervention:   Drug: inodiftagene vixteplasmid
  Sponsor:   Anchiano Therapeutics Israel Ltd.
  Recruiting
• Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

  NCT03716505

  Condition:   Migraine Disorders
  Interventions:   Device: gammaCore Sapphire active;   Device: gammaCore Sapphire Sham
  Sponsor:   ElectroCore INC
  Recruiting
• Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

  NCT03712345

  Conditions:   Granulomatosis With Polyangiitis (GPA);   Microscopic Polyangiitis (MPA)
  Interventions:   Drug: IFX-1;   Drug: Placebo
  Sponsors:   InflaRx GmbH;   Iqvia Pty Ltd
  Recruiting
• LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

  NCT03711929

  Condition:   Non Infectious Uveitis
  Interventions:   Drug: DE-109 Intravitreal Injections;   Other: Sham Procedure
  Sponsor:   Santen Inc.
  Recruiting
• Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

  NCT03664674

  Condition:   Meniere Disease
  Interventions:   Drug: OTO-104;   Drug: Placebo
  Sponsor:   Otonomy, Inc.
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

  NCT03656536

  Conditions:   Unresectable Cholangiocarcinoma;   Metastatic Cholangiocarcinoma
  Interventions:   Drug: Pemigatinib;   Drug: Gemcitabine;   Drug: Cisplatin
  Sponsor:   Incyte Corporation
  Recruiting
• Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

  NCT03628066

  Condition:   Breast Cancer
  Interventions:   Drug: Letrozole;   Drug: Palbociclib;   Drug: Goserelin;   Diagnostic Test: Oncotype DX Breast Recurrence Score
  Sponsors:   NSABP Foundation Inc;   Genomic Health®, Inc.;   Pfizer
  Recruiting
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

  NCT03619213

  Condition:   Heart Failure With Preserved Ejection Fraction
  Interventions:   Drug: Dapagliflozin;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT03611751

  Condition:   Psoriasis
  Interventions:   Drug: BMS-986165;   Other: Placebo;   Drug: Apremilast
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema

  NCT03610646

  Condition:   Diabetic Macular Edema
  Interventions:   Drug: MYL-1701P;   Drug: Eylea
  Sponsors:   Mylan Inc.;   Momenta Pharmaceuticals, Inc.
  Recruiting
• Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  NCT03609216

  Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
  Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

  NCT03607838

  Condition:   Lumbar Disc Herniation
  Interventions:   Drug: SI-6603;   Drug: Sham injection
  Sponsor:   Seikagaku Corporation
  Recruiting
• A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

  NCT03599713

  Condition:   Metastatic Merkel Cell Carcinoma
  Intervention:   Drug: INCMGA00012
  Sponsor:   Incyte Corporation
  Recruiting
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

  NCT03587805

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Tralokinumab
  Sponsor:   LEO Pharma
  Recruiting
• DEF-314 Better Accuracy in EF Assessment With DEFINITY

  NCT03571672

  Condition:   Cardiac Disease
  Intervention:   Drug: DEFINITY
  Sponsors:   Lantheus Medical Imaging;   Syneos Health
  Recruiting
• Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

  NCT03546816

  Conditions:   Pruritus;   Prurigo Nodularis
  Interventions:   Drug: 5mg Serlopitant Tablets;   Drug: Placebo Tablets
  Sponsor:   Menlo Therapeutics Inc.
  Recruiting
• Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

  NCT03521934

  Condition:   Heart Failure-Type 2 Diabetes Mellitus
  Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
  Sponsor:   Sanofi
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

  NCT03445533

  Condition:   Metastatic Melanoma
  Interventions:   Drug: Ipilimumab;   Drug: IMO-2125
  Sponsors:   Idera Pharmaceuticals, Inc.;   Bristol-Myers Squibb
  Recruiting
• Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

  NCT03433274

  Conditions:   Mitral Regurgitation;   Mitral Insufficiency;   Mitral Valve Insufficiency;   Cardiovascular Diseases;   Valve Disease, Heart;   Heart Valve Diseases;   Functional Mitral Regurgitation;   Degenerative Mitral Valve Disease
  Interventions:   Device: Tendyne Mitral Valve System;   Device: MitraClip System
  Sponsor:   Tendyne Holdings, Inc.
  Recruiting
• A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation

  NCT03382613

  Condition:   Atrial Fibrillation
  Intervention:  
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491

  Condition:   Pancreas Adenocarcinoma
  Interventions:   Device: NovoTTF-100L(P);   Drug: Gemcitabine;   Drug: nab paclitaxel
  Sponsor:   NovoCure Ltd.
  Recruiting
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

  NCT03371719

  Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
  Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702

  Condition:   Stage II Prostate Adenocarcinoma
  Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study to Test if Fremanezumab Reduces Headache in Patients With Posttraumatic Headache (PTH)

  NCT03347188

  Condition:   Post-Traumatic Headache
  Interventions:   Drug: Fremanezumab;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

  NCT03323151

  Condition:   Mantle-Cell Lymphoma
  Interventions:   Drug: Ixazomib;   Drug: Ibrutinib
  Sponsors:   PrECOG, LLC.;   Takeda
  Recruiting
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  NCT03298451

  Condition:   Hepatocellular Carcinoma
  Interventions:   Drug: Durvalumab;   Drug: Tremelimumab (Regimen 1);   Drug: Tremelimumab (Regimen 2);   Drug: Sorafenib;   Drug: Durvalumab (Regimen 1);   Drug: Durvalumab (Regimen 2)
  Sponsor:   AstraZeneca
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

  NCT03285308

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Placebo;   Drug: Atezolizumab
  Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Palbociclib in Real World Practice

  NCT03280303

  Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
  Intervention:   Other: non-interventional
  Sponsor:   Pfizer
  Recruiting
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554

  Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment

  NCT02827214

  Condition:   Thoracolumbar Burst Fracture
  Intervention:  
  Sponsors:   AO Clinical Investigation and Documentation;   AOSpine International
  Recruiting
• Heart Sounds Registry

  NCT03203629

  Condition:   Heart Failure; With Decompensation
  Intervention:   Device: Wearable Cardioverter Defibrillator (WCD)
  Sponsor:   Zoll Medical Corporation
  Recruiting
• A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

  NCT03143153

  Condition:   Various Advanced Cancer
  Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cisplatin;   Drug: Fluorouracil
  Sponsors:   Bristol-Myers Squibb;   Ono Pharmaceutical Co. Ltd
  Recruiting
• Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771

  Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

  NCT03105102

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab SC;   Drug: risankizumab IV;   Drug: placebo for risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

  NCT03070886

  Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
  Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT03043651

  Condition:   Pulmonary Hypertension Associated With HFpEF
  Intervention:   Drug: Oral Treprostinil
  Sponsor:   United Therapeutics
  Recruiting
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

  NCT03037580

  Conditions:   Pulmonary Hypertension;   Heart Failure With a Preserved Ejection Fraction
  Interventions:   Drug: Oral treprostinil;   Drug: Placebo
  Sponsor:   United Therapeutics
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

  NCT02997202

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: gilteritinib;   Drug: Placebo
  Sponsors:   Astellas Pharma Global Development, Inc.;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network
  Recruiting
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347

  Condition:   Treatment Naive Follicular Lymphoma
  Interventions:   Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
  Sponsor:   Pharmacyclics LLC.
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

  NCT02820363

  Condition:   Tibial Fracture
  Interventions:   Device: CERAMENT|G;   Procedure: SOC treatment
  Sponsor:   BONESUPPORT AB
  Recruiting
• RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

  NCT02818972

  Condition:   Aortic Aneurysm, Thoracic
  Intervention:   Device: RelayPro
  Sponsor:   Bolton Medical
  Recruiting
• Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

  NCT02810704

  Conditions:   Pulmonary Embolism;   Venous Thrombosis
  Interventions:   Drug: Enteric Coated Aspirin;   Drug: Warfarin;   Drug: Rivaroxaban
  Sponsors:   Medical University of South Carolina;   Patient-Centered Outcomes Research Institute;   University of Maryland, College Park;   Brigham and Women's Hospital;   Northwestern University Feinberg School of Medicine
  Recruiting
• Standardized Treatment of Pulmonary Exacerbations II

  NCT02781610

  Condition:   Pulmonary Cystic Fibrosis
  Intervention:   Drug: Standard of care IV antibiotic(s)
  Sponsors:   Chris Goss;   Cystic Fibrosis Foundation;   CF Therapeutics Development Network Coordinating Center;   Medical University of South Carolina;   University of Washington
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

  NCT02715284

  Condition:   Advanced or Metastatic Solid Tumors
  Intervention:   Biological: dostarlimab
  Sponsor:   Tesaro, Inc.
  Recruiting
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

  NCT02654990

  Condition:   Multiple Myeloma
  Interventions:   Drug: panobinostat capsules;   Drug: bortezomib injection;   Drug: dexamethasone tablets
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009

  Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

  NCT02577406

  Conditions:   Leukemia, Myeloid;   Isocitrate Dehydrogenase
  Interventions:   Drug: AG-221;   Other: BSC;   Drug: Azacitidine;   Drug: Low-dose cytarabine (LDAC);   Drug: Intermediate-dose cytarabine (IDAC)
  Sponsor:   Celgene
  Recruiting
• Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

  NCT02507687

  Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
  Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
  Sponsor:   Allergan
  Recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

  NCT02466971

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

  NCT02364557

  Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
  Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Expanded Clinical Study of the Tendyne Mitral Valve System

  NCT02321514

  Condition:   Mitral Valve Regurgitation
  Intervention:   Device: Tendyne Mitral Valve System
  Sponsor:   Tendyne Holdings, Inc.
  Recruiting
• A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

  NCT02236000

  Condition:   Breast Cancer
  Interventions:   Drug: Neratinib;   Drug: T-DM1
  Sponsors:   NSABP Foundation Inc;   Puma Biotechnology, Inc.
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

  NCT02004275

  Condition:   Multiple Myeloma in Relapse
  Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
  Recruiting
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

  NCT01996865

  Condition:   Lymphoma, Non-Hodgkin
  Interventions:   Drug: Lenalidomide;   Drug: Rituximab
  Sponsor:   Celgene
  Recruiting
• A Safety Study of SGN-LIV1A in Breast Cancer Patients

  NCT01969643

  Condition:   Breast Cancer
  Interventions:   Drug: SGN-LIV1A;   Drug: Trastuzumab
  Sponsor:   Seattle Genetics, Inc.
  Recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01896999

  Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561

  Condition:   Ulcerative Colitis (UC)
  Intervention:  
  Sponsor:   AbbVie
  Recruiting
• MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

  NCT01805076

  Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
  Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
  Recruiting
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

  NCT00887146

  Condition:   Brain and Central Nervous System Tumors
  Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
  Recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349

  Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
  Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866

  Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045

  Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
  Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
  Sponsor:   LivaNova
  Recruiting
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

  NCT03493685

  Condition:   Focal Segmental Glomerulosclerosis
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

  NCT03350828

  Condition:   Cystic Fibrosis
  Intervention:  
  Sponsors:   Nicole Hamblett;   Cystic Fibrosis Foundation
  Recruiting
• An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

  NCT03339297

  Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
  Interventions:   Drug: Defibrotide;   Drug: Standard of Care
  Sponsor:   Jazz Pharmaceuticals
  Recruiting
• An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

  NCT03290781

  Condition:   Ulcerative Colitis
  Interventions:   Drug: SHP647;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085

  Conditions:   Crohn's Disease;   Ulcerative Colitis
  Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
  Sponsor:   Shire
  Recruiting
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

  NCT03259334

  Condition:   Ulcerative Colitis
  Interventions:   Drug: SHP647;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

  NCT03181932

  Conditions:   MRSA;   Cystic Fibrosis
  Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
  Sponsor:   Savara Inc.
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  NCT03104413

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
  Sponsor:   AbbVie
  Recruiting
• A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

  NCT02815891

  Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431

  Condition:   Solid Tumors Harboring NTRK Fusion
  Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
  Sponsor:   Bayer
  Recruiting
• A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.

  NCT01792726

  Condition:   Early Breast Cancer
  Intervention:   Radiation: Boost to the tumour bed
  Sponsors:   University College, London;   National Institute for Health Research, United Kingdom
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting